Healthy lifestyle or Chronic Kidney Disease:The Choice is yours!

| June 3, 2019

article image
Chronic kidney disease (CKD) is a growing health problem with an estimated prevalence of around 11.5%.Individuals with CKD are at high risk for progressive kidney failure. End-stage kidney disease leads to considerable human and financial costs with a 5-year survival rate of less than 50%.  There are well-established risk factors for end-stage kidney disease of which Diabetes and hypertension are strong predictors for the development and progression of chronic kidney diseases and these in turn are closely linked to lifestyle factors. We have learned from research of other chronic conditions such as heart disease and cancer that lifestyle factors namely diet, physical activity, cigarette smoking, and body mass index plays a very important role in health outcomes namely cardiovascular events and mortality and kidney diseases are no exception to this rule. Over the next decade, the number of patients with end-stage renal disease requiring dialysis may double, and even developed nations will have difficulty coping with this alarming epidemic. There is an urgent need to highlight the importance of modifiable lifestyle risk factors as a basis for treatment strategies to prevent the development and progression of chronic kidney disease

Spotlight

SE Health

SE Health (Saint Elizabeth Health Care) is a social enterprise applying knowledge, vision and drive to forever impact how people live and age at home, today and into the future. With Canadian roots and 110 years of expertise, the not-for-profit organization brings quality excellence and innovation to home care, seniors lifestyle and family caregiving. Through its team of 9,000 Leaders of Impact, SE Health delivers 20,000 care exchanges daily, totaling 50 million in the last decade alone.

OTHER ARTICLES

Artificial intelligence in pharma: utilising a valuable resource

Article | March 11, 2020

The pharmaceutical industry is set to greatly benefit from the use of artificial intelligence (AI), due to its wide range of applications. Sydney Tierney discusses how machine learning can enhance marketing, manufacturing and drug trials. Artificial intelligence (AI) can be applied to nearly every aspect of the pharmaceutical and healthcare industry, to enhance data processing. Adopting the technology will reveal the astonishing potential of the healthcare sector, with success rates flying higher than ever before – especially in the research and development of crucial, life-changing drugs.

Read More

Clinical Development Risks and Issues in a COVID-19 World

Article | March 11, 2020

Global clinical guidelines have shifted the industry toward risk-based approaches for the planning and execution of clinical trials. The ICH’s guidelines for Good Clinical Practice state that sponsors should evaluate identified risks against existing risk controls by considering “the likelihood of errors occurring, the extent to which such errors would be detectable, and the impact of such errors on human subject protection and reliability of trial results” (ICH E6 R2).

Read More

Decentralized Clinical Trials: Imperative for Pharma Sector to fight COVID19

Article | March 11, 2020

These are unprecedented times. The world is mobbed by a contagion virus, putting people’s health at risk, threatening to destabilize economies. It has already put global healthcare systems under tremendous pressures, and managed to resist efforts to contain it. Even though coronaviruses are not new, this COVID-19 strain has created panic and forced us to be locked down in our homes sans any movement for weeks, if not months. Organizations are fighting an intense battle to keep their workforce safe, minimize risk, and ensure business continuity. For the Life Sciences industry, however, the challenge is even more significant. The whole world is looking at them to come up with a vaccine and a cure. But that is easier said than done. Bringing a new drug to market is an uphill battle and requires rigorous clinical trials. This process already has regulatory challenges. With the current lockdown situation, the Pharma community is grappled with the challenge of continuing some of the critical and time-sensitive in-flight trials so that their regulatory submission, registration, and market entry are not impacted. But all may not be lost. With the right technology solution, it is possible to turn the situation around rapidly.

Read More

How AI and Big Data Will Disrupt Pharma’s Regulatory Compliance Standards

Article | March 11, 2020

The industry as we know it is changing. Pharmaceutical and life sciences companies across the globe are experiencing more pressure than ever to keep up with increased regulatory standards while moving at a pace that requires them to innovate in order to remain competitive. With more real-time automation and the steady increase in AI and Big Data sweeping the landscape, what used to be a slow-to-change and risk-averse industry is now expected to see a significant shift towards newer technology that focus on heightened regulatory standards. Here’s how your company can get ahead of what industry experts are calling, Pharma

Read More

Spotlight

SE Health

SE Health (Saint Elizabeth Health Care) is a social enterprise applying knowledge, vision and drive to forever impact how people live and age at home, today and into the future. With Canadian roots and 110 years of expertise, the not-for-profit organization brings quality excellence and innovation to home care, seniors lifestyle and family caregiving. Through its team of 9,000 Leaders of Impact, SE Health delivers 20,000 care exchanges daily, totaling 50 million in the last decade alone.

Events